Genor Biopharma Holdings Ltd (6998)

Hong Kong
Currency in HKD
2.18
+0.04(+1.87%)
Closed
6998 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
2.132.30
52 wk Range
1.013.25
Key Statistics
Edit
Bid/Ask
2.15 / 2.18
Prev. Close
2.14
Open
2.14
Day's Range
2.13-2.3
52 wk Range
1.01-3.25
Volume
2M
Average Volume (3m)
463.7K
1-Year Change
86.09%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6998 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
No news in this category
Looks like there are no results in this news category

Genor Biopharma Holdings Company Profile

Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn’s disease, and fistulizing crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating breast cancer; and GB492, a stimulator of interferon genes in combination with GB226, which is under Phase 1/2 clinical trial to treat solid tumors. It also develops GB226, which is in Phase III clinical trial to treat 2L+ cervical cancer; in phase II trial to treat ASPS and r/r PMBCL; and in Phase I trial to treat 2L/3L+ EGFR+ NSCLC and 2L+ mCRC. In addition, the company develops GB261, which is in Phase I/II clinical trial to treat NHL; and GB263T that is in Phase I/II clinical trial to treat NSCLC. Further, it develops GB221, which is in Phase III clinical trial for the treatment of HER2 + 1L/2L+ mBC; GB223 that is in Phase I clinical trial to treat GCTB and PMO; GB241, which is in Phase III clinical trial to treat 1L DLBCL; and GB251 that is in Phase I clinical trial to treat HER2 + 1L/2L+ mBC. Additionally, the company’s product candidates under pre-clinical trials include GB262, GB264, GB266, GB267, and GB268 for the treatment of cancer. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.

Compare 6998 to Peers and Sector

Metrics to compare
6998
Peers
Sector
Relationship
P/E Ratio
−2.0x−13.6x−0.5x
PEG Ratio
−0.170.020.00
Price/Book
1.0x3.9x2.6x
Price / LTM Sales
72.6x11.0x3.0x
Upside (Analyst Target)
-23.7%54.7%
Fair Value Upside
Unlock3.7%9.3%Unlock

Earnings

Latest Release
Aug 26, 2021
EPS / Forecast
-0.82 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Genor Biopharma Holdings (6998) Stock Price Today?

The Genor Biopharma Holdings stock price today is 2.18.

What Stock Exchange Does Genor Biopharma Holdings Trade On?

Genor Biopharma Holdings is listed and trades on the Hong Kong stock exchange.

What Is the Stock Symbol for Genor Biopharma Holdings?

The stock symbol for Genor Biopharma Holdings is "6998."

What Is the Genor Biopharma Holdings Market Cap?

As of today, Genor Biopharma Holdings market cap is 1.11B.

What is Genor Biopharma Holdings Earnings Per Share?

The Genor Biopharma Holdings EPS is -1.03.

From a Technical Analysis Perspective, Is 6998 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.